A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine–refractory chronic idiopathic urticaria
Saini, Sarbjit, Rosen, Karin E., Hsieh, Hsin-Ju, Wong, Dennis A., Conner, Edward, Kaplan, Allen, Spector, Sheldon, Maurer, MarcusVolume:
128
Language:
english
Journal:
Journal of Allergy and Clinical Immunology
DOI:
10.1016/j.jaci.2011.06.010
Date:
September, 2011
File:
PDF, 598 KB
english, 2011